7Baggers
 Coya completes FTD combination therapy trial enrolment  Clinical Trials Arena Tue, 30 Sep 2025 08:09:36 GMT
 COYA Stock Analyst Rating: D. Boral Capital Maintains "Buy" Rati  GuruFocus Mon, 29 Sep 2025 15:14:22 GMT
 coya therapeutics (nasdaq:coya) trading up 3.4% - should you buy?  MarketBeat Sat, 27 Sep 2025 06:20:03 GMT
 carrying the als gene, leading the fight: daniel barvin named als hero  Jewish Herald-Voice Fri, 26 Sep 2025 05:05:26 GMT
 New trial to test effectiveness of COYA 302 to slow ALS progression  ALS News Today Thu, 25 Sep 2025 12:08:54 GMT
 Lucid Capital Reaffirms Their Buy Rating on Coya Therapeutics, Inc. (COYA)  The Globe and Mail Tue, 23 Sep 2025 07:00:00 GMT
 coya therapeutics (coya) analyst rating remains 'buy' amid consi  GuruFocus Mon, 22 Sep 2025 14:38:57 GMT
 Coya’s first results with COYA-303 in mouse model of inflammation  BioWorld MedTech Wed, 17 Sep 2025 13:00:00 GMT
 coya: analyst jason kolbert maintains 'buy' rating with $18 targ  GuruFocus Wed, 17 Sep 2025 12:57:56 GMT
 COYA: Chardan Capital Maintains Buy Rating with $14 Target | COY  GuruFocus Wed, 17 Sep 2025 07:00:00 GMT
 coya therapeutics highlights q2 2025 financial results  MSN Wed, 17 Sep 2025 04:44:33 GMT
 coya therapeutics highlights q2 2025 financial results  MSN Tue, 16 Sep 2025 13:37:47 GMT
 Coya Therapeutics names Arun Swaminathan as CEO  MSN Tue, 16 Sep 2025 00:30:12 GMT
 coya therapeutics highlights q2 2025 financial results  MSN Mon, 15 Sep 2025 17:26:21 GMT
 coya therapeutics highlights q2 2025 financial results  MSN Tue, 09 Sep 2025 18:59:19 GMT
 coya therapeutics highlights q2 2025 financial results  MSN Thu, 04 Sep 2025 09:06:29 GMT
 Coya gets FDA clearance to start Phase 2 trial of ALS treatment  ALS News Today Tue, 02 Sep 2025 07:00:00 GMT
 coya therapeutics receives $4.2m milestone payment  TipRanks Tue, 02 Sep 2025 07:00:00 GMT
 published on: 2025-08-29 09:21:59  beatles.ru Fri, 29 Aug 2025 05:21:59 GMT
 fda approves coya therapeutics’ trial of coya 302 for als  Indian Pharma Post Thu, 28 Aug 2025 07:00:00 GMT
 published on: 2025-08-27 10:39:29  Newser Wed, 27 Aug 2025 15:39:29 GMT
 Coya Therapeutics, Inc. (COYA) Now Trades Above Golden Cross: Time to Buy?  Zacks Investment Research Wed, 27 Aug 2025 07:00:00 GMT
 daniel barvin  BioSpace Tue, 26 Aug 2025 16:09:07 GMT
 h.c. wainwright reiterates buy rating on coya therapeutics stock with $18 target  Investing.com Nigeria Tue, 26 Aug 2025 10:01:24 GMT
 FDA approves Coya Therapeutics’ trial of COYA 302 for ALS  Clinical Trials Arena Tue, 26 Aug 2025 07:00:00 GMT
 after delay, coya receives fda go-ahead for ph. 2 als trial  Fierce Biotech Mon, 25 Aug 2025 15:04:26 GMT
 After delay, Coya receives FDA go-ahead for phase 2 ALS trial  Fierce Biotech Mon, 25 Aug 2025 07:00:00 GMT
 Coya Therapeutics stock soars after FDA accepts IND for ALS treatment  Investing.com Mon, 25 Aug 2025 07:00:00 GMT
 What's Going On With Coya Therapeutics Stock?  Benzinga Mon, 25 Aug 2025 07:00:00 GMT
 coya 302 heads to phase 2 trial of als following ind acceptance  Neurology Live Mon, 25 Aug 2025 07:00:00 GMT
 published on: 2025-08-20 06:04:05  Newser Wed, 20 Aug 2025 11:04:05 GMT

Coya Therapeutics Inc.
(NASDAQ:COYA) 


Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs).

Founded: 2020
Sector: LIFE SCIENCES
Industry: PHARMACEUTICAL PREPARATIONS

Share this website to your friends